Alembic Pharmaceuticals announced that Aleor Dermaceuticals (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies, has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with two observations.
The inspection was carried out from February 4, 2019 to February 8, 2019.
The stock had underperformed the market over the past one month till Feb. 11, 2019, falling 4.03% compared with the Sensex's 0.80% rise. It underperformed the market in past one quarter, declining 3.84% as against 3.52% rise in the Sensex.
